A nanotechnology-based immunotherapy, developed by researchers from the Icahn School of Medicine at Mount Sinai and tested in mice, is intended to inhibit organ rejection in transplant recipients without the side effects that typically result from traditional immunosuppressant drugs. Details of the research were published in Immunity.
Scientists test novel organ acceptance therapy in mice
Sign up for Sigma Xi SmartBrief
News on scientific research and innovation
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.